Neuphoria Therapeutics shares jumped while Scancell plunged, and the merger terms explain why

Scancell Holdings plc (AIM: SCLP) has agreed to acquire Neuphoria Therapeutics Inc. (Nasdaq: NEUP) through an all-share merger that could transform the British biotechnology company’s access to United States capital markets. The combined business plans to operate as Scancell, retain its AIM quotation and seek a Nasdaq listing under the proposed ticker SCLT. Alongside the merger, Scancell is targeting up to $89 million through equity placements, potential debt from funds managed by BlackRock and a minimum cash contribution from Neuphoria Therapeutics. The financing is intended primarily to carry the iSCIB1+ advanced melanoma program through a registrational Phase 3 readout expected in the second half of 2028 and support operations into 2029. The strategic logic is clear, but Scancell’s 17.65% share-price decline on July 23 showed that investors are concerned about discounted equity, dilution, debt exposure and the complexity of buying a largely restructured company to finance one major clinical program.

Why Scancell is using Neuphoria Therapeutics to reach Nasdaq and finance iSCIB1+

The proposed transaction is best understood as a capital-markets strategy rather than a conventional merger between two actively developing biotechnology pipelines. Scancell brings the operating business, oncology programs, clinical team and principal future value driver. Neuphoria Therapeutics contributes an existing Nasdaq-listed corporate structure, cash expected to remain at closing and contingent economic interests linked to partnered programs.

That structure gives Scancell a route to United States investors without pursuing a completely independent initial public offering. A Nasdaq listing could broaden the potential shareholder base beyond the United Kingdom, improve visibility among specialist healthcare funds and make future United States equity offerings easier to execute if iSCIB1+ advances successfully. Scancell intends to preserve its AIM listing, creating a dual-market structure rather than abandoning its existing British shareholder base.

The financing need is substantial because Scancell is preparing to move iSCIB1+ from an encouraging open-label Phase 2 program into a randomized global Phase 3 trial. The investigational therapy is an off-the-shelf DNA active immunotherapy designed to strengthen immune responses against melanoma-associated targets when used with checkpoint inhibitors. The United States Food and Drug Administration has cleared the Phase 3 program, while Scancell has also received Fast Track designation for iSCIB1+.

Scancell’s SCOPE Phase 2 study has generated encouraging progression-free survival signals in patients with advanced unresectable melanoma receiving iSCIB1+ or its predecessor alongside checkpoint therapy. Those results support a registrational trial, but the open-label, multicohort design does not provide the randomized control needed to determine precisely how much benefit iSCIB1+ adds to nivolumab and ipilimumab. The Phase 3 program will therefore decide whether the asset can move from promising clinical signal to a defensible regulatory and commercial proposition.

Scancell expects the combined financing package to support the program through its primary Phase 3 readout in the second half of 2028 and extend the company’s runway into 2029. That would remove a major near-term financing uncertainty and allow management to concentrate on patient recruitment, manufacturing and clinical execution. The benefit is meaningful because attempting to finance a global oncology trial through repeated small AIM offerings could create even greater dilution and expose the program to unpredictable market conditions.

The merger does not eliminate financing risk. It reorganizes that risk into a larger upfront transaction involving new shares, potential debt, warrants and future capital-market obligations. Scancell is effectively accepting a more complex capital structure in exchange for greater confidence that the Phase 3 program can reach its decisive readout.

How the $89 million package shifts risk from funding scarcity to dilution and debt

Scancell’s proposed funding package contains several separate components. The company has secured commitments for a $39.1 million private placement, plans a United Kingdom institutional placing of approximately $12 million and is seeking up to $3 million through a retail offer. It has also entered a non-binding term sheet with funds managed by BlackRock for as much as $25 million of debt, while Neuphoria Therapeutics is expected to contribute at least $10 million of cash at closing.

The equity portion provides permanent capital without scheduled repayment, but it materially expands Scancell’s share count. The United Kingdom placing was announced at 9 pence per share, well below Scancell’s previous closing price of 12.75 pence. That discount helps explain why Scancell shares fell to roughly 10.5 pence to 11 pence after the announcement, wiping out a substantial portion of the company’s pre-transaction market value in a single session.

The market was not necessarily rejecting the clinical program. Investors were repricing the ownership economics. New institutional investors are entering at a discounted valuation, existing Neuphoria Therapeutics shareholders will receive Scancell equity and additional shares will be issued through the United Kingdom placement and retail offer. Existing Scancell shareholders retain exposure to a better-funded company, but each pre-transaction share will represent a smaller percentage of the enlarged business.

Under the agreed exchange terms, each Neuphoria Therapeutics share is expected to convert into approximately 37.77199 Scancell American depositary shares, together with a contingent value right linked to specified Neuphoria Therapeutics assets and receipts. Existing Scancell shareholders are expected to control the majority of the combined company before the associated financing is fully reflected, while Neuphoria Therapeutics shareholders receive a minority position and continued exposure to selected legacy economics.

Scancell also plans a ten-for-one consolidation of its ordinary shares before completing the transaction. The consolidation does not alter the underlying enterprise value, but it should create a per-share price more suitable for Nasdaq trading and simplify the American depositary share structure. These technical changes are necessary for the cross-border listing, although they can make historical per-share comparisons more difficult for investors.

The proposed BlackRock financing introduces a different set of considerations. Debt may reduce the need for another immediate equity raise, but borrowed capital creates interest costs, repayment obligations and potential restrictions on corporate activity. The term sheet remains non-binding, meaning the final amount, pricing, security package and drawdown conditions may change or the financing may not close at all.

Scancell’s financing plan therefore contains a deliberate balance. Equity absorbs clinical risk without mandatory repayment, while debt limits immediate dilution but increases fixed financial obligations. The structure can work well if iSCIB1+ remains on schedule and produces positive Phase 3 results. Delays, recruitment problems or disappointing data would leave the company supporting an enlarged share base and possible debt without the asset revaluation needed to justify those commitments.

The announced funding package also depends on transaction conditions, including shareholder approvals, regulatory filings, Nasdaq acceptance and completion of sufficient financing. The headline figure of $89 million should therefore be viewed as the upper end of a proposed package rather than cash already deposited on Scancell’s balance sheet.

Why Neuphoria Therapeutics contributes cash and Nasdaq access rather than an active pipeline

Neuphoria Therapeutics entered the transaction after a difficult strategic reversal. Its AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder failed to meet both its primary and secondary endpoints in October 2025. The company halted development in social anxiety disorder, began reviewing strategic alternatives and later paused or cancelled most internal research activities.

By March 31, 2026, Neuphoria Therapeutics had terminated all but one employee, ended its facility leases and reduced its business to a structure designed largely to preserve cash and complete a strategic transaction. It reported $19.4 million in cash and cash equivalents and working capital of $20.1 million at that date. Scancell expects at least $10 million to remain at closing after Neuphoria Therapeutics’ operating, restructuring and transaction expenses.

This makes Neuphoria Therapeutics valuable for reasons different from those usually associated with a biotechnology acquisition. Scancell is not paying primarily to add BNC210 as a second major internally funded clinical asset. The combined company does not plan to allocate significant development capital to Neuphoria Therapeutics’ unpartnered programs and will focus resources on Scancell’s oncology portfolio.

Neuphoria Therapeutics still owns or participates in potentially valuable partnered economics. These include programs associated with Merck & Co., a KAT6 asset licensed through a collaboration involving Pfizer Inc. and potential Australian research and development tax receipts. Neuphoria Therapeutics received an Australian dollar 1.416 million distribution in May 2026 following the start of a Phase 3 study involving the Pfizer-partnered KAT6 program.

The merger’s contingent value rights are designed to separate those legacy assets from the principal Scancell investment proposition. Neuphoria Therapeutics shareholders can receive future cash payments if specified partnered programs, intellectual property rights or tax receivables generate value. Scancell shareholders are therefore not required to assign substantial upfront value to uncertain neuroscience and royalty assets, while Neuphoria Therapeutics investors retain a route to participate if those programs deliver payments.

This separation improves strategic clarity. The listed combined company can concentrate capital on iSCIB1+, Modi-1 and Scancell’s immunotherapy platforms, while the contingent rights preserve optionality around Neuphoria Therapeutics’ historical portfolio. The arrangement is especially important because reviving internal development of BNC210 would compete directly with the melanoma Phase 3 trial for management attention and funding.

Neuphoria Therapeutics is therefore functioning as a Nasdaq bridge, cash contributor and container for residual partnered rights. That may sound less glamorous than a pipeline merger, but it can still be economically rational when a clinical-stage biotechnology company needs a United States listing and substantial capital more urgently than it needs additional experimental drugs.

What the opposite Scancell and Neuphoria share-price reactions reveal about investor sentiment

Scancell shares fell 17.65% on July 23, closing around 10.5 pence to 11 pence and reducing the company’s market capitalization to approximately £109 million to £112 million. Trading volume rose sharply as investors processed the discounted equity issuance, acquisition terms and potential debt.

Neuphoria Therapeutics shares moved in the opposite direction, rising approximately 17.7% to $3.92 after trading as high as $4.36. The company’s market capitalization was approximately $21.5 million at the latest trade. Neuphoria Therapeutics shareholders gained a route out of a heavily restructured standalone company and into a funded late-stage oncology business, while retaining contingent rights tied to selected legacy assets.

The diverging reactions reflect where the economic burden falls. Scancell shareholders are providing the operating platform and absorbing most of the dilution, financing and Phase 3 execution risk. Neuphoria Therapeutics shareholders are receiving equity in the combined company and optional future payments after their own lead program failed and internal development was largely suspended.

The Scancell decline may also reflect concerns that the 9 pence financing price established a lower near-term valuation benchmark. Investors purchasing shares before the announcement faced immediate dilution from capital raised below the previous market price. Even shareholders who support the strategic rationale may have reduced positions while waiting for clarity on final financing terms, ownership percentages and the BlackRock debt documentation.

The negative market response does not prove that the transaction destroys long-term value. A fully funded registrational program and Nasdaq listing could be worth substantially more than preserving a higher share price while remaining dependent on serial small financings. The merger’s success will be judged by whether Scancell can use the capital to reach the Phase 3 readout without another major rescue financing.

The next market tests will include shareholder approval, completion of the private placement and United Kingdom offering, execution of definitive debt agreements, confirmation of the Nasdaq listing and initiation of the iSCIB1+ Phase 3 study. Recruitment progress and updated mature SCOPE data will determine whether investors begin viewing the discounted financing as a strategic entry point or as the beginning of a longer dilution cycle.

Scancell has chosen scale and funding certainty over a simpler capital structure. That decision increases the company’s ability to run the trial that could define its future, but it also concentrates value around one clinical outcome. If iSCIB1+ succeeds, the merger may look like a creative solution to the financing constraints facing European biotechnology companies. If the program disappoints, the expanded share count, debt and transaction complexity will magnify the consequences.

Key takeaways from the Scancell and Neuphoria Therapeutics merger and financing plan

• Scancell Holdings is acquiring Neuphoria Therapeutics primarily to obtain Nasdaq access, additional cash and a United States capital-markets structure rather than to add another actively funded internal pipeline.
• The combined company plans to trade on Nasdaq under the proposed ticker SCLT while retaining Scancell’s AIM listing, giving it access to both British and United States biotechnology investors.
• Scancell is targeting up to $89 million through private placement capital, a United Kingdom placing, a retail offer, potential BlackRock-managed debt and at least $10 million of Neuphoria Therapeutics cash.
• The funding could support the iSCIB1+ Phase 3 melanoma program through its expected primary readout in the second half of 2028 and extend the combined company’s runway into 2029.
• Scancell’s 17.65% share-price decline reflected concern about equity issued at 9 pence, dilution for existing shareholders, possible debt obligations and execution risk surrounding the transaction.
• Neuphoria Therapeutics shares rose approximately 17.7% because the merger gives its investors ownership in a funded oncology company after BNC210 failed in Phase 3 and most internal development was suspended.
• Neuphoria Therapeutics had only one employee and $19.4 million in cash at March 31, confirming that the transaction is not a traditional merger of two fully operating biotechnology organizations.
• Contingent value rights allow Neuphoria Therapeutics shareholders to retain exposure to selected partnered assets, intellectual property receipts and tax credits without forcing Scancell to prioritize those programs.
• The transaction can create value if Scancell completes the financing, starts Phase 3 on schedule and avoids another major capital raise before the iSCIB1+ readout.
• The investment case remains concentrated around whether randomized Phase 3 data confirm the melanoma benefit suggested by Scancell’s open-label SCOPE study.